Tomoyuki Mizuno

List of Publications by Citations

Source: https://exaly.com/author-pdf/6449561/tomoyuki-mizuno-publications-by-citations.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73 papers	1,671 citations	21 h-index	39 g-index
85 ext. papers	2,150 ext. citations	4.2 avg, IF	4.63 L-index

#	Paper	IF	Citations
73	Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. *Cancer Chemotherapy and Pharmacology*, **2012**, 70, 399-405	3.5	212
72	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. *Therapeutic Drug Monitoring*, **2019**, 41, 261-307	3.2	163
71	Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. *Molecular Pharmacology*, **2009**, 75, 1280-6	4.3	147
70	1543. Ceftaroline Model-based Dose Individualization in an Infant with Kidney Disease and Mediastinitis. *Open Forum Infectious Diseases*, **2019**, 6, S563-S563	1	78
69	Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics. *Drug Metabolism and Pharmacokinetics*, **2012**, 27, 631-9	2.2	75
68	OCT1 genetic variants influence the pharmacokinetics of morphine in children. *Pharmacogenomics*, **2013**, 14, 1141-51	2.6	73
67	Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. *Clinical Pharmacokinetics*, **2014**, 53, 185-96	6.2	60
66	ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children. *Pharmacogenomics*, **2014**, 15, 1297-309	2.6	58
65	ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. *Annals of Oncology*, **2010**, 21, 1382-1383	10.3	47
64	Dual imaging of pulmonary delivery and gene expression of dry powder inhalant by fluorescence and bioluminescence. *Journal of Controlled Release*, **2009**, 134, 149-54	11.7	47
63	Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies. *Pediatric Blood and Cancer*, **2017**, 64, e26470	3	46
62	Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. *American Journal of Hematology*, **2019**, 94, 871-879	7.1	35
61	Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study. *Journal of Pediatrics*, **2015**, 167, 1214-20.e3	3.6	34
60	The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma. *Therapeutic Drug Monitoring*, **2014**, 36, 310-6	3.2	32
59	OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children. *Pharmacogenomics*, **2017**, 18, 621-629	2.6	28
58	Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Lessons From PBPK Modeling and Clinical Study. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 761-768	6.1	27
57	Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. *British Journal of Clinical Pharmacology*, **2016**, 81, 742-52	3.8	26

56	Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies. *European Journal of Pharmaceutical Sciences*, **2017**, 109S, S124-S131	5.1	25
55	Pharmacokinetics of IGF-1 in PAPP-A2-Deficient Patients, Growth Response, and Effects on Glucose and Bone Density. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 4568-4577	5.6	24
54	ABCC3 genetic variants are associated with postoperative morphine-induced respiratory depression and morphine pharmacokinetics in children. *Pharmacogenomics Journal*, **2017**, 17, 162-169	3.5	21
53	Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial. *PLoS Medicine*, **2017**, 14, e1002428	11.6	21
52	Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve gastrectomy. *Clinical Transplantation*, **2017**, 31, e12975	3.8	20
51	A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. *Neuro-Oncology*, **2020**, 22, 1527-1535	1	20
50	Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2020**, 26, 429-439	4.5	20
49	Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of sunitinib in rats. *Drug Metabolism and Disposition*, **2013**, 41, 1592-7	4	17
48	Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study. *International Journal of Clinical Oncology*, **2010**, 15, 512-4	4.2	17
47	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. *Therapeutic Drug Monitoring*, **2021**, 43, 150-200	3.2	17
46	Learning Health Systems as Facilitators of Precision Medicine. *Clinical Pharmacology and Therapeutics*, **2017**, 101, 359-367	6.1	16
45	Characterizing the Developmental Trajectory of Sirolimus Clearance in Neonates and Infants. *CPT: Pharmacometrics and Systems Pharmacology*, **2016**, 5, 411-7	4.5	16
44	Developmental trajectory of intestinal MDR1/ABCB1 mRNA expression in children. *British Journal of Clinical Pharmacology*, **2014**, 77, 910-2	3.8	16
43	Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation of clinical trial simulations. *Journal of Clinical Pharmacology*, **2016**, 56, 291-7	2.9	16
42	Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients. *Journal of Thrombosis and Thrombolysis*, **2017**, 44, 38-47	5.1	15
41	Electronic Health Record-Embedded Decision Support Platform for Morphine Precision Dosing in Neonates. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 186-194	6.1	15
40	MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase. *Clinical Pharmacology and Therapeutics*, **2020**, 108, 635-643	6.1	13
39	Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib. *Pediatric Blood and Cancer*, **2019**, 66, e27618	3	12

38	Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 1639-1647	6.1	12
37	Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group. *British Journal of Clinical Pharmacology*, **2017**, 83, 1097-1107	3.8	11
36	Acute Kidney Injury Biomarkers Predict an Increase in Serum Milrinone Concentration Earlier Than Serum Creatinine-Defined Acute Kidney Injury in Infants After Cardiac Surgery. *Therapeutic Drug Monitoring*, **2018**, 40, 186-194	3.2	11
35	Retrospective Evaluation of Milrinone Pharmacokinetics in Children With Kidney Injury. *Therapeutic Drug Monitoring*, **2015**, 37, 792-6	3.2	11
34	Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1. *Therapeutic Drug Monitoring*, **2015**, 37, 395-9	3.2	9
33	Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery. *Clinical Pharmacokinetics*, **2019**, 58, 793-803	6.2	9
32	Fatty acid amide hydrolase-morphine interaction influences ventilatory response to hypercapnia and postoperative opioid outcomes in children. *Pharmacogenomics*, **2017**, 18, 143-156	2.6	8
31	Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediatric patients with acute lymphoblastic leukemia. *European Journal of Pharmaceutical Sciences*, **2019**, 128, 209-214	5.1	6
30	Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care. *British Journal of Clinical Pharmacology*, **2020**,	3.8	6
29	Sorafenib in a hepatocellular carcinoma patient with end-stage renal failure: A pharmacokinetic study. *Hepatology Research*, **2014**, 44, 685-8	5.1	6
28	A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. *Pediatric Blood and Cancer*, **2021**, 68, e28787	3	6
27	Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and Pediatric Patients. *Journal of Clinical Pharmacology*, **2020**, 60, 992-998	2.9	5
26	Pharmacokinetics and pharmacogenomics of β-lactam-induced neutropenia. *Pharmacogenomics*, **2016**, 17, 547-59	2.6	5
25	Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics. *Expert Opinion on Drug Metabolism and Toxicology*, **2021**, 17, 87-103	5.5	5
24	Opportunities for model-based precision dosing in the treatment of sickle cell anemia. *Blood Cells, Molecules, and Diseases*, **2017**, 67, 143-147	2.1	4
23	Model-Informed Bayesian Estimation Improves the Prediction of Morphine Exposure in Neonates and Infants. *Therapeutic Drug Monitoring*, **2020**, 42, 778-786	3.2	4
22	Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome. *Clinical Pharmacokinetics*, **2021**, 60, 249-259	6.2	4
21	Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial. *Intensive Care Medicine*, **2018**, 44, 2006-2008	14.5	4

20	PK/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision Dosing. *Frontiers in Pharmacology*, **2020**, 11, 605060	5.6	3
19	Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients. *British Journal of Clinical Pharmacology*, **2020**, 86, 933-943	3.8	3
18	Molecular Adsorbent Recirculating System Therapy with Continuous Renal Replacement Therapy Enhanced Clearance of Piperacillin in a Pediatric Patient and Led to Failure to Attain Pharmacodynamic Targets. *Pharmacotherapy*, **2020**, 40, 1061-1068	5.8	3
17	Route of Oseltamivir Administration Affects Metabolite Concentrations in Critically Ill Children. *Pediatric Infectious Disease Journal*, **2019**, 38, 1224-1227	3.4	3
16	Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for patients with hepatoblastoma. *Pediatric Blood and Cancer*, **2019**, 66, e27425	3	3
15	Sirolimus Treatment in Sturge-Weber Syndrome. *Pediatric Neurology*, **2021**, 115, 29-40	2.9	3
14	Individualized Dosing of Hydroxyurea for Children with Sickle Cell Anemia Using a Population Pharmacokinetic-Based Model: The TREAT Study. *Blood*, **2016**, 128, 3652-3652	2.2	2
13	Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome. *Clinical Pharmacology and Therapeutics*, **2021**,	6.1	2
12	A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome. *Pharmacology & Therapeutics*, **2021**, 108045	13.9	2
11	Next Challenge From the Variance in Individual Physiologically-Based Pharmacokinetic Model-Predicted to Observed Morphine Concentration in Critically Ill Neonates. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 319-320	6.1	2
10	Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide management. *British Journal of Clinical Pharmacology*, **2018**, 84, 1410-1412	3.8	1
9	Clinical and Laboratory Benefits of Early Initiation of Hydroxyurea with Pharmacokinetic Guided Dosing for Young Children with Sickle Cell Anemia. *Blood*, **2018**, 132, 507-507	2.2	1
8	Toward pharmacogenetic SLCO1B1-guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model. *Clinical and Translational Science*, **2021**, 14, 2267-2277	4.9	1
7	Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease.. *Alimentary Pharmacology and Therapeutics*, **2021**,	6.1	1
6	Population pharmacokinetics of vancomycin in paediatric patients with febrile neutropenia and augmented renal clearance: development of new dosing recommendations. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 2932-2940	5.1	0
5	Leukopenia With Mycophenolate in Calcineurin Inhibitor-Free, Corticosteroid-Free Renal Transplant Recipients.. *Transplantation*, **2014**, 98, 549	1.8	
4	Mycophenolate Pharmacokinetics in Calcineurin Inhibitor-Free, Corticosteroid-Free Renal Transplant Recipients.. *Transplantation*, **2014**, 98, 550	1.8	
3	Kidney Injury Molecule-1 and its association with delayed clearance and drug exposure in pediatric oncology patients treated with high dose methotrexate.. *Journal of Clinical Oncology*, **2015**, 33, 10034-10034	2.2	

2	Pharmacogenetic variants associated with differential sirolimus clearance in pediatric patients.. *Journal of Clinical Oncology*, **2015**, 33, 2562-2562	2.2
1	1004: INADEQUATE MEROPENEM TARGET ATTAINMENT EARLY IN PEDIATRIC CRITICAL ILLNESS. *Critical Care Medicine*, **2022**, 50, 499-499	1.4